Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma

Human Gene Therapy

Volumn 24, Issue 3, 2013, Pages 306-316

  Knoop, Kerstin ^a   Schwenk, Nathalie ^a   Dolp, Patrick ^a   Willhauck, Michael J ^a   Zischek, Christoph ^b   Zach, Christian ^b   Hacker, Markus ^b   Göke, Burkhard ^a   Wagner, Ernst ^b   Nelson, Peter J ^b   Spitzweg, Christine ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; IODINE 131; RANTES; RHENIUM 188; SODIUM IODIDE SYMPORTER;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GAMMA CAMERA; GENE TARGETING; GENE TRANSFER; GENETIC ENGINEERING; HALF LIFE TIME; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SCINTIGRAPHY; THERAPY EFFECT; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MESENCHYMAL STROMAL CELLS; MICE; POSITRON-EMISSION TOMOGRAPHY; RNA, MESSENGER; SYMPORTERS; TISSUE DISTRIBUTION; TISSUE THERAPY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 84875427091     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.104     Document Type: Article

References (52)

1. Aquino, J.., Bolontrade, M.F., Garcia, M.G., et al. (2010). Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma. Gene Ther. 17, 692-708.
2. Braunersreuther, V., Viviani, G.L., Mach, F., and Montecucco, F. (2012). Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 18, 727-735.
3. Conrad, C., Gupta, R., Mohan, H., et al. (2007). Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther. 7, 249-260.
4. Conrad, C., Huesemann, Y., Niess, H., et al. (2011). Linking Transgene Expression of Engineerd Mesenchymal Stem Cells and Angiopoietin-1-induced Differentiation to Target Cancer Angiogenesis. Ann Surg. 253, 566-571.
5. Dadachova, E., Bouzahzah, B., Zuckier, L.S., and Pestell, R.G. (2002). Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol. 29, 13-18.
6. Dadachova, E., Nguyen, A., Lin, E.Y., et al. (2005). Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl Med Biol. 32, 695-700.
7. Denhardt, D.T., Lopez, C.A., Rollo, E.E., et al. (1995). Osteopontininduced modifications of cellular functions. Ann N Y Acad Sci. 760, 127-142.
8. Di Cosmo, C., Liao, X.H., Dumitrescu, A.M., et al. (2009). A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology 150, 4450-4458.
9. Dingli, D., Russell, S.J., and Morris, J.C. (2003). In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem. 90, 1079-1086.
10. Dwyer, R.M., Bergert, E.R., O'Connor M, K., et al. (2005a). In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res. 11, 1483-1489.
11. Dwyer, R.M., Schatz, S.M., Bergert, E.R., et al. (2005b). A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer. Mol Ther. 12, 835-841.
12. Dwyer, R.M., Khan, S., Barry, F.P., et al. (2010). Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res Ther. 1, 25.
13. Dwyer, R.M., Ryan, J., Havelin, R.J., et al. (2011). Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer. Stem Cells 29, 1149-1157.
14. Edelmann, S.L., Nelson, P.J., and Brocker, T. (2011). Comparative promoter analysis in vivo: identification of a dendritic cell-specific promoter module. Blood 118, e40-e49.
15. Grone, H.J., Weber, C., Weber, K.S., et al. (1999). Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J. 13, 1371-1383.
16. Groot-Wassink, T., Aboagye, E.O., Wang, Y., et al. (2004). Quantitative imaging of Na/I symporter transgene expression using positron emission tomography in the living animal. Mol. Therapy 9, 436-442.
17. Herve, J., Cunha, A.S., Liu, B., et al. (2008). Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther. 19, 915-926.
18. Hingorani, M., Spitzweg, C., Vassaux, G., et al. (2010). The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr. Cancer Drug Targets 10, 242-267.
19. Kakinuma, H., Bergert, E.R., Spitzweg, C., et al. (2003). Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. Cancer Res. 63, 7840-7844.
20. Karar, J., and Maity, A. (2009). Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther. 8, 1994-2001.
21. Karnoub, A.E., Dash, A.B., Vo, A.P., et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-563.
22. Klopp, A.H., Spaeth, E.L., Dembinski, J.L., et al. (2007). Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res. 67, 11687-11695.
23. Klutz, K., Russ, V., Willhauck, M.J., et al. (2009). Targeted radioiodine therapy of neuroblastoma tumors following systemic nonviral delivery of the sodium iodide symporter gene. Clin Cancer Res. 15, 6079-6086.
24. Klutz, K., Willhauck, M.J., Wunderlich, N., et al. (2011). Sodium iodide symporter (NIS)-mediated radionuclide ((131)I, (188)Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery. Hum Gene Ther. 22, 1403-1412.
25. Knoop, K., Kolokythas, M., Klutz, K., et al. (2011). Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated NIS gene delivery. Mol Ther. 19, 1704-1713.
26. Li, H., Peng, K.W., Dingli, D., et al. (2010). Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy. Cancer Gene Ther. 17, 550-558.
27. Mascia, F., Mariani, V., Girolomoni, G., and Pastore, S. (2003). Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am. J. Pathol. 163, 303-312.
28. McAllister, S.S., Gifford, A.M., Greiner, A.L., et al. (2008). Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 133, 994-1005.
29. Mi, Z., Bhattacharya, S.D., Kim, V.M., et al. (2011). Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis 32, 477-487.
30. Nelson, P.J., Kim, H.T., Manning, W.C., et al. (1993). Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol. 151, 2601-2612.
31. Niess, H., Bao, Q., Conrad, C., et al. (2011). Selective targeting of genetically engineered mesenchymal stem cells to tumor stroma microenvironments using tissue-specific suicide gene expression suppresses growth of hepatocellular carcinoma. Ann Surg. 254, 767-774.
32. Parkin, D.M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108.
33. Peerlinck, I., Merron, A., Baril, P., et al. (2009). Targeted radionuclide therapy using a Wnt-targeted replicating adenovirus encoding the Na/I symporter. Clin Cancer Res. 15, 6595-6601.
34. Pinilla, S., Alt, E., Abdul Khalek, F.J., et al. (2009). Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett. 284, 80-85.
35. Pinter, M., Hucke, F., Graziadei, I., et al. (2012). Advanced-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization versus Sorafenib. Radiology 263, 590-599.
36. Scholz, I.V., Cengic, N., Baker, C.H., et al. (2005). Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther. 12, 272-280.
37. Spaeth, E., Klopp, A., Dembinski, J., et al. (2008). Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 15, 730-738.
38. Spaeth, E.L., Dembinski, J.L., Sasser, A.K., et al. (2009). Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4, e4992.
39. Spitzweg, C., Zhang, S., Bergert, E.R., et al. (1999). Prostatespecific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 59, 2136-2141.
40. Spitzweg, C., O'Connor, M.K., Bergert, E.R., et al. (2000). Treatment of prostate cancer by radioiodine therapy after tissuespecific expression of the sodium iodide symporter. Cancer Res 60, 6526-6530.
41. Spitzweg, C., Dietz, A.B., O'Connor, M.K., et al. (2001). In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 8, 1524-1531.
42. Spitzweg, C., and Morris, J.C. (2002). The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin. Endocrinol. (Oxf) 57, 559-574.
43. Spitzweg, C., Baker, C.H., Bergert, E.R., et al. (2007). Imageguided radioiodide therapy of medullary thyroid cancer after carcinoembryonic antigen promoter-targeted sodium iodide symporter gene expression. Hum. Gene Ther. 18, 916-924.
44. Van Sande, J., Massart, C., Beauwens, R., et al. (2003). Anion selectivity by the sodium iodide symporter. Endocrinology 144, 247-252.
45. Von Luttichau, I., Notohamiprodjo, M., Wechselberger, A., et al. (2005). Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev. 14, 329-336.
46. Wapnir, I.L., Goris, M., Yudd, A., et al. (2004). The Na +/Isymporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid. Clin Cancer Res. 10, 4294-4302.
47. Willhauck, M.J., Sharif-Samani, B.R., Gildehaus, F.J., et al. (2007). Application of 188Re as an Alternative Radionuclide for Treatment of Prostate Cancer after Tumor-Specific Sodium Iodide Symporter Gene Expression. J. Clin. Endocrinol Metab. 92, 4451-4458.
48. Willhauck, M.J., Samani, B.R., Wolf, I., et al. (2008a). The potential of 211Astatine for NIS-mediated radionuclide therapy in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1272-1281.
49. Willhauck, M.J., Sharif-Samani, B., Senekowitsch-Schmidtke, R., et al. (2008b). Functional sodium iodide symporter expression in breast cancer xenografts in vivo after systemic treatment with retinoic acid and dexamethasone. Breast Cancer Res. Treat. 109, 263-272.
50. Willhauck, M.J., Sharif Samani, B.R., Klutz, K., et al. (2008c). Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther. 15, 214-223.
51. Zischek, C., Niess, H., Ischenko, I., et al. (2009). Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann. Surg. 250, 747-753.
52. Zlotnik, A., and Yoshie, O. (2000). Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127.